PharmEnable Limited has announced a collaboration with Denali Therapeutics, for neurodegenerative diseases. In this collaboration, PharmEnable will leverage its proprietary AI drug discovery platform with Denali's expertise in delivery across the BBB and neurodegeneration to identify therapeutically relevant small molecule chemical matter against challenging targets. The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme.

Denali will be responsible for the further lead optimisation, development, and commercialisation of these molecules. Under the terms of the agreement, PharmEnable will receive an upfront cash payment and will be eligible to receive development and commercial milestone payments.